))
Ep. 204: Exciting Updates from AAAAI 2024
Manage episode 404214686 series 3392202
Content provided by FAACT's Roundtable Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by FAACT's Roundtable Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Learn about ground-breaking news and updates from the recent American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting held this February in Washington, D.C. In lay relatable terms, FAACT’s Medical Advisory Board Chair, Dr. Shahzad Mustafa, discusses the approval of Xolair and what it means for the food allergy community. He also shares his thoughts regarding treatments that are on-the-horizon for anaphylaxis from ARS Pharma, Bryn Pharma, Aquestive, DBV Technologies, and Blueprint Medicines.
Resources to keep you in the know:
- New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies (Genentech)
- ARS Pharma
- Bryn Pharma
- Aquestive
- DBV Technologies
- Blueprint Medicines
- Takeda (EOHILIA)
- FAACT's Resources:
You can also find FAACT’s Roundtable Podcast on Apple Podcast, Spotify, iHeart Radio, Podcast Chaser, Deezer, Tune-In, Alexa, and Listen Notes or wherever you listen to podcasts.
Follow us on Facebook, X (formerly known as Twitter), Instagram, Threads, LinkedIn, Pinterest, TikTok, and
Thanks for listening! FAACT invites you to discover more exciting food allergy resources at FoodAllergyAwareness.org!
212 episodes
Share
